Covid-19 vaccination eligibility notice

This Weekly’s Hot Topics

  • Letter from MOASC President MOASC News
  • Covid-19 vaccination eligibility notice California News
  • PHE will likely continue through the end of 2021 National News
  • Submit ASCO abstracts by February 17, 2021 Affiliate Association News/ANCO News

Targeted Oncology has a DTC program February 4 for MOASC members. This program is open to, and intended for, oncologists treating DTC. The Case-Based Peer Perspectives Roundtable virtual meeting will feature a thought leader in the field who will discuss pathology report findings, patient diagnostic workup, the most likely diagnosis and potential treatment options for a few case studies. To read more click here and go to MOASC News/MOASC Programs.

The state has developed a new website (myturn.ca.gov) that will enable residents to determine their eligibility to be vaccinated and to sign up to be notified when they do become eligible, so they can then schedule an appointment. The new site also provides a mechanism to easily track vaccination data and enables providers to automatically share data on vaccines received and administered with the state. To read more click here and go to California News.

As the U.S. continues to grapple with the COVID-19 pandemic, ASCO strongly encourages practices to participate in the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) to help examine the evidence on the effect of COVID-19 on patients with cancer. The ASCO Registry collects baseline and longitudinal data on patients with cancer and COVID-19 and plans to deliver periodic reports with key findings that can influence future care. Thanks to support from Conquer Cancer, the ASCO Foundation, ASCO provides payments (both for start-up and for each patient entered) to help cover expenses involved in participating. To read more click here and go to Affiliate Association News/ASCO News.

To read the complete California Oncology Newsletter, click on the date below.

January 2, 2021



No comments have been posted yet.